文献速递肺结节与肺癌

优化疑似肺癌的诊断与分期路径:一项决策分析

Optimizing Diagnostic and Staging Pathways for Suspected Lung Cancer: A Decision Analysis.
PubMed 文献 · Chest · 2021-07-10

该研究通过决策模型比较16种支气管镜与CT引导活检等组合策略在疑似肺癌患者中的成本效果。结果显示,外周病灶且影像N0时最佳支气管镜策略比最佳CTBx策略贵1694美元但并发症更少;中央病灶或N1-3时凸性支气管内超声联合ROSE最具成本效果;ROSE策略始终更优。

要点

  • 外周病灶影像N0时,最佳支气管镜策略比最佳CTBx贵1694美元,但并发症风险低14%。
  • 中央病灶或影像N1-3时,凸性支气管内超声联合ROSE比任何CTBx策略更具成本效果。
  • 无论何种场景,含ROSE的策略始终比不含ROSE的策略更具成本效果。

核心结论

  • 最具成本效果的策略取决于淋巴结分期、病灶位置、外周支气管镜活检类型及是否使用ROSE。

研究设计与样本

  • 基于高概率肺癌的假设患者构建决策模型,评估16种支气管镜联合透视、径向支气管内超声、电磁导航、凸性支气管内超声(伴或不伴ROSE)、CT引导活检及手术的独特组合。

主要发现

  • 外周病灶且影像N0时,最佳支气管镜策略比最佳CTBx策略成本高1694美元,但并发症风险差异为14%。
  • 为避免一例CTBx策略相关并发症,支气管镜策略需额外花费12037美元。
  • 小病灶时支气管镜策略的成本和累积并发症较CTBx策略增加;存在支气管征时成本和累积并发症降低,但总体仍更昂贵。
  • 中央病灶和/或影像N1-3时,凸性支气管内超声联合ROSE后必要时行肺活检的策略在所有结局上均比任何CTBx策略更具成本效果。
  • 无论何种场景,含ROSE的策略始终比不含ROSE的策略更具成本效果。

临床怎么用

  • 临床选择诊断与分期路径时应综合考虑淋巴结分期、病灶位置、外周支气管镜活检类型及是否使用ROSE。
  • 多数临床场景下可排除许多策略,并对剩余竞争策略的权衡进行量化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal diagnostic and staging strategy for patients with suspected lung cancer is not known. RESEARCH QUESTION: What diagnostic and staging strategies are most cost-effective for lung cancer? STUDY DESIGN AND METHODS: A decision model was developed by using a hypothetical patient with a high probability of lung cancer. Sixteen unique permutations of bronchoscopy with fluoroscopy, radial endobronchial ultrasound, electromagnetic navigation, convex endobronchial ultrasound with or without rapid-onsite evaluation (ROSE), CT-guided biopsy (CTBx), and surgery were evaluated. Outcomes included cost, complications, mortality, time to complete the evaluation, rate of undetected N2-3 disease at surgery, incremental cost-complication ratio, and willingness-to-pay thresholds. Sensitivity analyses were performed on primary outcomes. RESULTS: For a peripheral lung lesion and radiographic N0 disease, the best bronchoscopy strategy costs $1,694 more than the best CTBx strategy but resulted in fewer complications (risk difference, 14%). The additional cost of bronchoscopy to avoid one complication from a CTBx strategy was $12,037. The cost and cumulative complications of bronchoscopy strategies increased compared with CTBx strategies for small lesions. The cost and cumulative complications of bronchoscopy strategies decreased compared with CTBx strategies when a bronchus sign was present, but bronchoscopy remained more costly overall. For a central lesion and/or radiographic N1-3 disease, convex endobronchial ultrasound with ROSE followed by lung biopsy with incremental cost-effectiveness ratio, if required, was more cost-effective than any CTBx strategy across all outcomes. Strategies with ROSE were always more cost-effective than those without, irrespective of scenario. Trade-offs also exist between different bronchoscopy strategies, and optimal choices depend on the value placed on individual outcomes and willingness-to-pay. INTERPRETATION: The most cost-effective strategies depend on nodal stage, lesion location, type of peripheral bronchoscopic biopsy, and the use of ROSE. For most clinical scenarios, many strategies can be eliminated, and trade-offs between the remaining competitive strategies can be quantified.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Vakil E, Jackson N, Sainz-Zuñega PV, et al. Optimizing Diagnostic and Staging Pathways for Suspected Lung Cancer: A Decision Analysis. Chest. 2021. PMID: 34256049. doi:10.1016/j.chest.2021.06.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。